Get the Stockscreener App
94.90
0.32%
0.30
After Hours:
94.90
Merus N V stock is traded at $94.90, with a volume of 2.03M.
It is up +0.32% in the last 24 hours and up +37.76% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$94.60
Open:
$94.62
24h Volume:
2.03M
Relative Volume:
0.98
Market Cap:
$7.18B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.03
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.32%
1M Performance:
+37.76%
6M Performance:
+109.58%
1Y Performance:
+79.67%
1-Day Range:
$94.58
$94.96
1-Week Range:
$94.38
$95.06
52-Week Range:
$33.19
$95.06
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.90 | 7.17B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Aug-25-25 | Initiated | Alliance Global Partners | Buy |
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
What market sentiment indicators show for Merus N.V. (2GH) stockNew Guidance & Low Risk Entry Point Tips - newser.com
Will Merus N.V. stock sustain high P E ratios2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
What risks investors should watch in Merus N.V. stockWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com
Can Merus N.V. stock double in next 5 yearsJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Is Merus N.V. stock a buy before product launches2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Why Merus N.V. stock remains on buy listsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Is Merus N.V. stock resilient to inflationJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Market reaction to Merus N.V.’s recent newsWeekly Market Outlook & Stock Portfolio Risk Control - newser.com
Why Merus N.V. (2GH) stock could outperform next year2025 Market Outlook & Daily Technical Stock Forecast Reports - newser.com
Can Merus N.V. (2GH) stock sustain revenue momentumDay Trade & AI Enhanced Execution Alerts - newser.com
Key metrics from Merus N.V.’s quarterly dataMarket Performance Report & High Accuracy Trade Alerts - newser.com
Why Merus N.V. stock appeals to dividend seekers2025 Price Targets & Capital Protection Trade Alerts - newser.com
Is Merus N.V. stock a dividend growth opportunity2025 Fundamental Recap & Stock Portfolio Risk Management - Fundação Cultural do Pará
Merus N.V.’s Zenocutuzumab Study Termination: Market Implications - TipRanks
Will Merus N.V. stock deliver better than expected guidanceWeekly Stock Report & Technical Confirmation Trade Alerts - newser.com
Is Merus N.V. stock attractive for income investorsEarnings Performance Report & Fast Entry Momentum Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stock2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
2.47%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):